Cancer Vaccine Maker Dendreon Corporation Can't Meet Demand
Published: Jun 28, 2010
Portfolio.com -- Dendreon Corp. raised more than $400 million in a secondary offering last December to build factories so it could produce enough of its prostate cancer vaccine. At the time, the product wasn't even approved. Now that the vaccine Provenge is being sold, the company can't keep up with demand.